You are here: Industry Insights > Catalent

News List

Optima Supports Catalent with High-Speed Vial Filling Line contractpharma
June 19, 2020
Prepares for large-scale commercial manufacturing of a lead vaccine candidate for COVID-19.
Catalent, AstraZeneca Ink Mfg. Pact for COVID-19 Vax contractpharma
June 16, 2020
Catalent preparing for large-scale commercial supply of the University of Oxford’s COVID-19 vaccine candidate AZD1222 starting August 2020.
Catalent Enters COVID-19 Vax Pact with Spicona contractpharma
June 11, 2020
Will leverage GPEx cell line development platform to develop COVID-19 vaccine.
Catalent Names Charles Lickfold as Chief Information Officer contractpharma
June 03, 2020
Catalent has appointed Charles Lickfold as senior vice president, chief information officer. Mr. Lickfold succeeds John McGill, who, following a period of transition, plans to retire in September 2020.
Catalent Acquires Clinical Packaging Facility in Japan contractpharma
May 26, 2020
Establishes a new clinical GMP manufacturing and distribution hub to support local and global clinical studies.
Triphase, Catalent Announce Interim TRPH-222 Results in NHL contractpharma
May 20, 2020
TRPH-222 leverages Catalent’s SMARTag platform to provide optimized site-specific protein-modification and linker technologies.
Catalent, Ennaid Therapeutics collaborate to develop antiviral treatment for Covid-19 disease pharmaceutical-business-review
May 18, 2020
Catalent has collaborated with speciality pharmaceutical company Ennaid Therapeutics for the development of an oral and antiviral treatment for Covid-19 disease.
Catalent, Ennaid Therapeutics Ink COVID-19 Program Pact contractpharma
May 14, 2020
Catalent will develop a powder-in-capsule formulation of Ennaid’s ENU200 program, a repurposed antiviral drug for the potential treatment of COVID-19.
Catalent Provides Clinical Support for COVID-19 Study contractpharma
May 11, 2020
Partners with Humanigen for FDA-approved Phase 3 lenzilumab study for COVID-19 patients.
Arcturus Therapeutics, Catalent announce partnership to manufacture mRNA-based Covid-19 pharmaceutical-business-review
May 08, 2020
Arcturus Therapeutics Holdings, a leading clinical-stage messenger RNA (mRNA) medicines and vaccines company, and Catalent announced a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19) .

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page